LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
The LumiraDx CRP diagnostic test combines speed and test sensitivity at the point of need, empowering doctors to make informed decisions on antibiotic prescriptions 1,2,
The test provides actionable results to care providers at a variety of clinical settings including ICUs, paediatric d... (more)
Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19
LumiraDx’s microfluidic technology and innovative Point of Care (POC) Platform supports a broad menu of tests with lab-comparable performance, at ... (more)
